Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.
The Ewha Medical Journal
Ewha Womans University School of Medicine

Ewha Med J 1984; 7(4):227-233

pISSN: 1598-7450

DOI: https://doi.org/10.12771/emj.1984.7.4.227

Original Article

Viral Serologic Markers in Patients with Acute and Chronic Liver Diseases

Il Hwan Moon, Gap Ho Lee, Lee Gap Park
Corresponding author: Lee Gap Park. Department of Internal Medicine, College of Medicine, Ewha Womans University, Korea.

Copyright ⓒ 1984. Ewha Womans University School of Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published Online: Jul 24, 2015

Abstract

Vial serologic markers for hepatitis B virus infection are known as HBsAg, anti-HBs, anti-HBc and anti-HBe, and also recently IgM class antibodies are measurable for both hepatitis A and B. Five serologic markers for hepatitis B virus infection were measured routinely in patients with acute and chronic liver diseases and IgM class antibodies were evaluated in patients with acute viral hepatitis. The results were as follows: 1) Men are more frequently affected than women in chronic liver diseases and as the disease progressed to chronic diseases, the mean ages of patients increased. 2) Positivities of HBsAg were 79.7% in acute viral hepatitis, 88.9% in chronic hepatitis, 47.2% in cirrhosis and 72.0% in primary liver cancer respectively. 3) In forty cases of acute viral hepatitis, IgM anti-HBe was positive in two HBsAg negative cases and negative in three HBsAg positive cases. 4) Anti-HBc was positive in majority of various liver diseases and appeared usually with HBsAg or anti-HBs,but sigly positive in minority of patients. 5) Positivities of HBeAg in HBsAg positive liver diseases were 68.1% in acute viral hepatitis, 75.0% in chronic hepatitis, 41.2% in cirrhosis and 61.1% in primary liver cancer respectively.